NVS Jan 2024 90.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:31AM EDT. Market open.
| Previous close | 5.95 |
| Open | 6.10 |
| Bid | 6.40 |
| Ask | 8.90 |
| Strike | 90.00 |
| Expiry date | 2024-01-19 |
| Day's range | 6.10 - 6.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 465 |
- Zacks
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
- Zacks
Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint
Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.
- Zacks
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
© 2022 Yahoo. All rights reserved.
